Announcements Trials
Browse Landscape

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 25Observational 2

Sponsor

Conditions

Breast Neoplasms 693Neoplasms 610Prostatic Neoplasms 320Lung Neoplasms 309Colorectal Neoplasms 281Carcinoma, Non-Small-Cell Lung 253Pancreatic Neoplasms 178Carcinoma, Hepatocellular 169Stomach Neoplasms 143Multiple Myeloma 127Ovarian Neoplasms 121Melanoma 116Colonic Neoplasms 114Brain Neoplasms 108Hematologic Neoplasms 106Head and Neck Neoplasms 103Urinary Bladder Neoplasms 102Leukemia, Myeloid, Acute 100Esophageal Neoplasms 100Disease 97Liver Neoplasms 92Uterine Cervical Neoplasms 90Neoplasm Metastasis 89Lymphoma 86Rectal Neoplasms 85Precursor Cell Lymphoblastic Leukemia-Lymphoma 82Endometrial Neoplasms 78Carcinoma, Renal Cell 74Leukemia 65Sarcoma 63

Interventions

Olanzapine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Observational × Nausea × 1 year × Clear all
NCT07403370 2026-05-19

Olanzapine Dose Comparison for the Prevention of HER-INV: A Network Meta-Analysis

Shandong Cancer Hospital and Institute

Completed
2,000 enrolled

Nausea, Vomiting

NCT01440465 2025-12-17

NAVI

Centre Francois Baclesse

Completed
300 enrolled 7 charts

Nausea, Neoplasms, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡